top of page

Free Biopharma Daily Stock Updates - 11/05/21

$XBI $131.32 -1.42%

 

Covid Updates

$OCGN Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years. source


$NRXP US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure. source



Pipeline Updates

$HGEN Humanigen Announces Release of Abstracts at ASH. source


$OCUL Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®. source


$OMER Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial. source


$OMER Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis. source


$CHRS Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022. source


$ARDX Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021. source


$EQ Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting. source


$CASI CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021. source


$NTLA Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting. source


$CALA Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial. source


$DCPH Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study. source


$BCRX BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat). source


$AZN AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021. source


$ANGN Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study. source



Financial Updates

$CRDL Cardiol Therapeutics Announces Closing of US$50 Million Public Offering. source


$EVAX Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering. source


$MRUS Merus Announces Pricing of Public Offering of Common Shares. source

 

Posted by FS/DV

0 comments
bottom of page